T1	p 84 119	advanced nasopharyngeal carcinoma :
T2	p 187 219	Nasopharyngeal carcinoma ( NPC )
T3	p 382 419	patients with advanced NPC . PATIENTS
T4	p 432 551	From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC
T5	p 1845 1890	patients with advanced NPC in endemic areas .
T6	i 25 79	concurrent chemoradiotherapy versus radiotherapy alone
T7	i 308 378	concurrent chemoradiotherapy ( CCRT ) versus radiotherapy ( RT ) alone
T8	i 628 630	RT
T9	i 710 751	concurrent chemotherapy with cisplatin 20
T10	i 763 787	/d plus fluorouracil 400
T11	i 813 823	continuous
T12	i 861 865	RT .
T13	i 1376 1380	CCRT
T14	i 1625 1637	chemotherapy
T15	i 1812 1816	CCRT
T16	o 93 107	nasopharyngeal
T17	o 139 178	overall and progression-free survival .
T18	o 866 883	Survival analysis
T19	o 1141 1154	tumor relapse
T20	o 1208 1237	5-year overall survival rates
T21	o 1317 1355	5-year progression-free survival rates
T22	o 1468 1481	more toxicity
T23	o 1520 1554	leukopenia and emesis , compliance
T24	o 1743 1767	treatment-related deaths